Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 1.00 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252058 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OGA | |
| SCHEMBL3252059 | 1.00 | SIGMAR1 (1.00) | SIGMAR1OGA | |
| SCHEMBL11795394 | 0.85 | SIGMAR1 (0.74) | SIGMAR1 | |
| SCHEMBL11795413 | 0.85 | SIGMAR1 (0.74) | SIGMAR1 | |
| SCHEMBL11795403 | 0.85 | SIGMAR1 (0.74) | SIGMAR1 | |
| SCHEMBL11787522 | 0.82 | SIGMAR1 (0.69) | SIGMAR1 | |
| SCHEMBL11787525 | 0.82 | SIGMAR1 (0.69) | SIGMAR1 | |
| SCHEMBL11787517 | 0.82 | SIGMAR1 (0.69) | SIGMAR1 | |
| SCHEMBL103704 | 0.81 | SIGMAR1 (0.68) | SIGMAR1 | |
| SCHEMBL15679632 | 0.81 | SIGMAR1 (0.68) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-4041038-A | ANESTHETICS | KYORIN PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
| US-3962249-A | 1-(3-PHENYLPROPYL)-4-FUROYLPIPERAZINE DERIVATIVES | KYORIN SEIYAKU KABUSHIKI KAISHA (JA) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | SIGMAR1 38/4885OGA 758/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | SIGMAR1 102/4885OGA 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.